Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 22 Oct, 01:30 am
Stifel Financial (NYSE: SF) reported adjusted earnings of $1.46 per share , slightly above the $1.45 analyst estimate. Net revenue totaled $1.43 billion , about 1% below the $1.45 billion consensus estimate. The company reported higher profit, growing client assets and a strategi
Goldman Sachs analyst George Tong raised his price target for MSCI (NYSE: MSCI) to $684.00 from $672.00 . MSCI reported strong third-quarter results, with Revenue climbing 12% year over year to $892.00 million and Adjusted earnings per share increasing 14% to $5.11 . Management a
Orrstown Financial Services (NASDAQ: ORRF) surpassed analyst expectations for its third-quarter 2026 adjusted earnings and revenue. The company reported significant financial improvements, including increased net income, a higher tax-equivalent net interest margin, and an improve
D.A. Davidson downgraded Braze (NASDAQ: BRZE) to Neutral, setting a $47.50 price target. Reports indicate Salesforce (NYSE: CRM) is acquiring Braze for approximately $5.66 billion , causing a significant surge in Braze's stock. On the news, Braze's stock soared 51.7% , while peer
Goldman Sachs reiterated a Neutral rating on Equifax (NYSE: EFX) , indicating a hold action on the stock. Equifax reported robust third-quarter 2026 revenue of $1.693 billion , marking a 10% increase year-over-year. The company demonstrated strong performance in key segments, wit
Insider Sale: Venture Global (NYSE: VG) 's Chief Financial Officer sold 111,111 Class A shares, totaling approximately $1.41 million , leaving him with no holdings. Mixed Market Signals: Despite a recent 9.3% decline in its stock price, technical analysis (hammer candlestick) and
CIBC has initiated coverage on Equinix (NASDAQ:EQIX) , a leading data center REIT, with an Outperform rating. The company demonstrates strong year-to-date stock performance and offers a notable dividend per share, positioning it as a potential income investment in the digital inf
An executive at Cytokinetics (NASDAQ:CYTK) sold 3,500 shares for approximately $224,035.00 . The company's heart disease treatment, Myqorzo, is expanding its market reach with strong U.S. prescription rates and international approvals. Cytokinetics exhibits a trailing price-to-ea
Q3 Earnings Miss: Grupo Aeroportuario del Pacífico (NYSE: PAC) reported Q3 earnings per share of $2.66 and revenue of $632.90 million , both falling short of analyst estimates. Revenue Growth: Despite missing estimates, the company achieved higher revenue and profitability year-o
Northern Trust (NASDAQ: NTRS) is set to report its third-quarter 2026 earnings, with analysts projecting strong growth in both earnings per share and revenue. Key drivers for this anticipated growth include significant increases in projected net interest income and total fee inco
WISeSat.Space Holdings (NASDAQ: SAIQ) more than doubled following an update on satellite cybersecurity testing. Braze (NASDAQ: BRZE) surged 51.7% after Salesforce agreed to acquire the company for approximately $5.66 billion . Myriad Genetics (NASDAQ: MYGN) gained 31.6% after agr
Picard Medical (NYSE American: PMI) led the selected decliners, falling 32.2% amid continued volatility. Sea Limited (NYSE: SE) dropped 9.1% on trading volume exceeding four times its recent average. Leveraged inverse ETFs LABD (NYSE Arca: LABD) , BMNZ (NYSE Arca: BMNZ) and SMST
Iridium Communications (NASDAQ: IRDM) reported robust Q3 2026 results, with initial earnings per share of $0.98 significantly exceeding the $0.34 estimate. The company's revenue reached $245.70 million , surpassing the $236.30 million estimate. Despite differing figures, Iridium
Wall Street anticipates Moody's (NYSE: MCO) to report Q3 2026 earnings of $4.25 per share on revenue of approximately $2.08 billion . Key revenue drivers include demand for credit ratings and growth in Moody's Analytics, particularly from recurring subscriptions and AI tools, des
Investment firm Raymond James increased its price target for Rapport Therapeutics (NASDAQ: RAPP) to $86.00 , reflecting strong analyst confidence in the biopharmaceutical company. The upward revision follows positive Phase 2 clinical trial results for its lead candidate, RAP-219,
Heartland Express (NASDAQ: HTLD) reported third-quarter revenue and earnings below analysts’ estimates. Revenue declined 8.7% year over year, but the company returned to profitability with net income of $1.0 million . The operating ratio improved by 500 basis points to 98.7
United Airlines (NASDAQ: UAL) is set to report Q3 earnings with analyst estimates projecting $2.57 to $2.60 EPS and revenue around $17.90 billion . Despite resilient revenue growth, higher fuel costs and inflation are pressuring profits, leading to a 6.9% drop in EPS estimates. U
Piper Sandler upgraded Myriad Genetics (NASDAQ: MYGN) to Neutral from Underweight, setting a $5.00 price target. Myriad Genetics is selling its prenatal health testing business to Labcorp for $210.00 million in cash. This strategic divestiture is expected to improve Myriad Geneti
Headlines provided by Investing.com